Kobayashi Pharmaceutical Co., Ltd.
KBYPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $290,815 | $36,411,000 | $32,607,000 | $51,141,000 |
| % Growth | -99.2% | 11.7% | -36.2% | – |
| Cost of Goods Sold | $139,560 | $16,949,000 | $15,924,000 | $26,234,000 |
| Gross Profit | $151,255 | $19,462,000 | $16,683,000 | $24,907,000 |
| % Margin | 52% | 53.5% | 51.2% | 48.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | -$14,534,000 |
| SG&A Expenses | $118,483 | $15,293,000 | $14,203,000 | $2,335,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $16,869,000 |
| Other Operating Expenses | $0 | $56,000 | -$55,000 | $14,688,000 |
| Operating Expenses | $118,483 | $15,349,000 | $14,148,000 | $17,023,000 |
| Operating Income | $32,772 | $4,113,000 | $2,535,000 | $7,884,000 |
| % Margin | 11.3% | 11.3% | 7.8% | 15.4% |
| Other Income/Exp. Net | $1,149 | -$1,607,000 | -$792,000 | -$1,249,000 |
| Pre-Tax Income | $33,922 | $2,506,000 | $1,743,000 | $6,635,000 |
| Tax Expense | $9,268 | $965,000 | $120,000 | $1,909,000 |
| Net Income | $24,627 | $1,543,000 | $1,624,000 | $4,723,000 |
| % Margin | 8.5% | 4.2% | 5% | 9.2% |
| EPS | 0.33 | 20.76 | 21.85 | 63.53 |
| % Growth | -98.4% | -5% | -65.6% | – |
| EPS Diluted | 0.33 | 20.76 | 21.85 | 63.53 |
| Weighted Avg Shares Out | 74,339 | 74,337 | 74,339 | 74,338 |
| Weighted Avg Shares Out Dil | 74,339 | 74,337 | 74,339 | 74,338 |
| Supplemental Information | – | – | – | – |
| Interest Income | $575 | $392,000 | $53,000 | $48,000 |
| Interest Expense | $20 | $0 | $0 | $5,000 |
| Depreciation & Amortization | $14,642 | $2,156,000 | $2,005,500 | $2,005,500 |
| EBITDA | $48,604 | $6,325,000 | $4,485,500 | $8,645,500 |
| % Margin | 16.7% | 17.4% | 13.8% | 16.9% |